Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting

New data on multiple Bristol-Myers Squibb Company (NYSE:BMY) compounds will be presented at the 61^st annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 29 to November 2.

“Bristol-Myers Squibb is focused on developing innovative medicines to treat liver disease”

Data will be presented on BARACLUDE^® (entecavir) in patients with chronic hepatitis B, and on compounds in clinical development for the treatment of hepatitis C, using multiple scientific approaches to target the hepatitis C virus (HCV). Key hepatitis C presentations include data on novel combinations of investigational agents, including BMS-790052, a NS5A inhibitor, and BMS-650032, an NS3 inhibitor. Additionally, 12-week Phase 2a data on PEG-Interferon lambda, a novel type 3 interferon with enhanced specificity for hepatocyte binding, will be presented.

The Company will also present outcomes research data in both hepatitis C and hepatocellular carcinoma.

"Bristol-Myers Squibb is focused on developing innovative medicines to treat liver disease," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. "Building on our established expertise in viral hepatitis and oncology, the data at this year's Liver Meeting demonstrates the breadth and strength of our hepatitis C portfolio. We are pursuing multiple targets with the potential to be used in combination regimens to advance the treatment of this serious disease."

BARACLUDE, BMS-790052, and BMS-650032 were discovered by Bristol-Myers Squibb Research and Development. PEG-Interferon lambda was discovered by ZymoGenetics, Inc. Bristol-Myers Squibb and ZymoGenetics announced a global collaboration for PEG-Interferon lambda and its related development program in 2009. In September 2010, Bristol-Myers Squibb announced its intent to acquire ZymoGenetics.

The Bristol-Myers Squibb data presentations at AASLD are as follows: